Morning Watch List: Highpower International (NASDAQ:HPJ), Esperion Therapeutics (NASDAQ:ESPR), Johnson & Johnson (NYSE:JNJ), BioTelemetry (NASDAQ:BEAT), CDI Corp. (NYSE:CDI)

On Friday shares of Highpower International, Inc. (NASDAQ:HPJ) closed at $4.81. Company’s sales growth for last 5 years was 15.90%. Highpower International, Inc. (NASDAQ: HPJ) announced on 1 May, that it has secured a contract to produce a 100KWH energy storage system (ESS) for China Southern Power Grid Co., Ltd. (CSPG). This ESS system is designed to maintain a balance of supply and demand over the south China grid as part of a long-term energy storage project developed by CSPG.

Esperion Therapeutics, Inc. (NASDAQ:ESPR) in last trading activity increased 3.56% to close at $103.54. Company weekly performance is 3.13% while its quarterly performance stands at 74.34%. Esperion Therapeutics, Inc. (NASDAQ:ESPR) is -12.96% away from its 52 week high. Esperion Therapeutics, Inc. (NASDAQ: ESPR), today provided ETC-1002 (bempedoic acid) development program updates and financial results for the first quarter ended March 31, 2015. “Esperion had another truly transformational quarter,” said Tim M. Mayleben, president and chief executive officer of Esperion. “Following the recently announced positive Phase 2b add-on to statin clinical study results of ETC-1002, we are actively preparing to meet with FDA in the third quarter and eager to advance ETC-1002 into Phase 3 development before year end.

On Friday shares of Johnson & Johnson (NYSE:JNJ) closed at $101.47. Company’s sales growth for last 5 years was 3.70% and EPS growth for next 5 years is recorded as 5.13%. Johnson & Johnson (NYSE: JNJ) on 7 May, announced a first-of-its-kind partnership that enlists a third party to review requests made to the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen) for compassionate use of its investigational medicines. This new approach will begin as a pilot program focused on a single Janssen investigational medicine and, if successful, will become a model that will be applicable more broadly across Johnson & Johnson.

BioTelemetry, Inc. (NASDAQ:BEAT) has 6.10% insider ownership while its institutional ownership stands at 71.50%. In last trading activity company’s stock closed at $9.36. BioTelemetry Inc. (NASDAQ:BEAT) on 6 May, reported a loss of $69,000 in its first quarter. The Malvern, Pennsylvania-based company said it had a loss of less than 1 cent on a per-share basis. Earnings, adjusted for non-recurring costs, came to 6 cents per share.

On last trading day CDI Corp. (NYSE:CDI) increased 0.74% to close at $13.68. Its volatility for the week is 3.78% while volatility for the month is 3.08%. CDI’s sales growth for past 5 years was 4.90% and its EPS growth for past 5 years was 16.60%. CDI Corp. (NYSE:CDI) monthly performance is -1.23%. CDI Corp. (NYSE: CDI) announced that its Board of Directors has authorized a second quarter 2015 dividend of $0.13 per share. The dividend is payable on June 2, 2015, to holders of record as of the close of business on May 19, 2015.

Leave a Reply

Your email address will not be published. Required fields are marked *